Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641126 | 0.80 | GALR3 (0.39) | GALR3KDM4EMAPT | |
| SCHEMBL58879 | 0.78 | GALR3 (0.38) | GALR3KDM4EKMT2A | |
| SCHEMBL15282119 | 0.72 | GALR3 (0.34) | GALR3KMT2A | |
| SCHEMBL3095819 | 0.68 | ALDH1A1 (0.33) | GALR3MAPT | |
| SCHEMBL1257988 | 0.68 | GALR3 (0.31) | GALR3 | |
| SCHEMBL21240594 | 0.65 | GALR3 (0.33) | GALR3 | |
| SCHEMBL9629226 | 0.65 | KDM4E (0.36) | GALR3KDM4EKMT2AMAPT | |
| SCHEMBL5280090 | 0.64 | — | — | |
| SCHEMBL9044558 | 0.62 | — | — | |
| SCHEMBL35451 | 0.61 | KMT2A (0.34) | GALR3KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112521402-A | 1,2, 4-oxadiazole [5,5] bicyclic fused ring compound and preparation method thereof | 北京理工大学 | 2021-03-19 | — | — | CN | claimed |
| CN-112521402-A | 1,2, 4-oxadiazole [5,5] bicyclic fused ring compound and preparation method thereof | 北京理工大学 | 2021-03-19 | — | — | CN | disclosed |
| US-20210053925-A1 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3746423-A1 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE DERIVATIVES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2020-12-09 | — | — | EP | disclosed |
| CN-111655670-A | Process for preparing 2-chloro-4-nitroimidazole derivatives | 大塚制药株式会社 | 2020-09-11 | — | — | CN | disclosed |
| WO-2019146113-A1 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-08-01 | — | — | WO | disclosed |
| US-7569702-B2 | Method for producing 4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070161802-A1 | Method for producing 4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1720838-B1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1720838-A1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077913-A1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053925-A1 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE DERIVATIVES | TALDO1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CTPS2 | GALR3 4865/4885KDM4E 1570/4885KMT2A 1765/4885 |
| US-20070161802-A1 | Method for producing 4-nitroimidazole compound | COX4I1, GTF3C5, CYP4X1 | GALR3 3470/4885KDM4E 1752/4885KMT2A 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.